Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: A methodological approach
Background Assessing the quality of mass drug administration (MDA) rounds is a key component of lymphatic filariasis (LF) elimination programs. Routine collection of administrative coverage is unreliable, especially when pockets with low program coverage exist. To address this gap, we used lot quali...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2020-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500667/?tool=EBI |
| _version_ | 1819028404943454208 |
|---|---|
| author | Milika Rinamalo Lorenzo Pezzoli Mike Kama Eric Rafai Ilisapeci Kubuabola Mosese Salusalu Sung Hye Kim Mary Hamer Hodges |
| author_facet | Milika Rinamalo Lorenzo Pezzoli Mike Kama Eric Rafai Ilisapeci Kubuabola Mosese Salusalu Sung Hye Kim Mary Hamer Hodges |
| author_sort | Milika Rinamalo |
| collection | DOAJ |
| description | Background Assessing the quality of mass drug administration (MDA) rounds is a key component of lymphatic filariasis (LF) elimination programs. Routine collection of administrative coverage is unreliable, especially when pockets with low program coverage exist. To address this gap, we used lot quality assurance sampling (LQAS) following the 10th annual LF-MDA round in Fiji to explore whether there was any area in which target coverage was not reached. We also assessed the level of drug compliance and satisfaction with the LF-MDA implementation strategy. Methodology/principal findings We conducted a cross-sectional household survey in 3 divisions of Fiji. For LQAS, we defined 19 lots in 7 medical areas of the Suva sub-division and another 12 sub-divisions in the Central, Northern, and Eastern Divisions. A sample of 16 randomly selected household members was taken un each lot. We defined our decision rule as follows: if more than 1 person in a given lot did not swallow the medication, coverage was considered inadequate, i.e. less than 80%. Of the 7 lots in Suva sub-division and 12 lots in the 3 divisions, five and two lots, respectively, were identified as having inadequate coverage. The overall program coverage estimated from 304 samples was 92%, which was higher than the reported administrative coverage of 82%. About 98% of interviewees were offered the medication and 96% swallowed it. Non-participation arose from insufficient information on how to obtain the drugs. At least 92% were satisfied with the LF-MDA implementation strategy. Conclusions Areas of low program coverage with results discordant with the reported administrative coverage existed in both urban and rural settings. Drug compliance and satisfaction were high, even after repeated rounds. We recommend increasing efforts to deliver the service in those areas with inadequate program coverage, as well as conducting timely coverage assessment through LQAS for corrective action. |
| first_indexed | 2024-12-21T05:57:50Z |
| format | Article |
| id | doaj.art-328206a858474e1aac9385ef143ab692 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-21T05:57:50Z |
| publishDate | 2020-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-328206a858474e1aac9385ef143ab6922022-12-21T19:13:49ZengPublic Library of Science (PLoS)PLoS ONE1932-62032020-01-01159Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: A methodological approachMilika RinamaloLorenzo PezzoliMike KamaEric RafaiIlisapeci KubuabolaMosese SalusaluSung Hye KimMary Hamer HodgesBackground Assessing the quality of mass drug administration (MDA) rounds is a key component of lymphatic filariasis (LF) elimination programs. Routine collection of administrative coverage is unreliable, especially when pockets with low program coverage exist. To address this gap, we used lot quality assurance sampling (LQAS) following the 10th annual LF-MDA round in Fiji to explore whether there was any area in which target coverage was not reached. We also assessed the level of drug compliance and satisfaction with the LF-MDA implementation strategy. Methodology/principal findings We conducted a cross-sectional household survey in 3 divisions of Fiji. For LQAS, we defined 19 lots in 7 medical areas of the Suva sub-division and another 12 sub-divisions in the Central, Northern, and Eastern Divisions. A sample of 16 randomly selected household members was taken un each lot. We defined our decision rule as follows: if more than 1 person in a given lot did not swallow the medication, coverage was considered inadequate, i.e. less than 80%. Of the 7 lots in Suva sub-division and 12 lots in the 3 divisions, five and two lots, respectively, were identified as having inadequate coverage. The overall program coverage estimated from 304 samples was 92%, which was higher than the reported administrative coverage of 82%. About 98% of interviewees were offered the medication and 96% swallowed it. Non-participation arose from insufficient information on how to obtain the drugs. At least 92% were satisfied with the LF-MDA implementation strategy. Conclusions Areas of low program coverage with results discordant with the reported administrative coverage existed in both urban and rural settings. Drug compliance and satisfaction were high, even after repeated rounds. We recommend increasing efforts to deliver the service in those areas with inadequate program coverage, as well as conducting timely coverage assessment through LQAS for corrective action.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500667/?tool=EBI |
| spellingShingle | Milika Rinamalo Lorenzo Pezzoli Mike Kama Eric Rafai Ilisapeci Kubuabola Mosese Salusalu Sung Hye Kim Mary Hamer Hodges Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: A methodological approach PLoS ONE |
| title | Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: A methodological approach |
| title_full | Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: A methodological approach |
| title_fullStr | Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: A methodological approach |
| title_full_unstemmed | Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: A methodological approach |
| title_short | Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: A methodological approach |
| title_sort | lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in fiji a methodological approach |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500667/?tool=EBI |
| work_keys_str_mv | AT milikarinamalo lotqualityassurancesamplingtoassesscoverageandcompliancefollowingmassdrugadministrationtoeliminatelymphaticfilariasisinfijiamethodologicalapproach AT lorenzopezzoli lotqualityassurancesamplingtoassesscoverageandcompliancefollowingmassdrugadministrationtoeliminatelymphaticfilariasisinfijiamethodologicalapproach AT mikekama lotqualityassurancesamplingtoassesscoverageandcompliancefollowingmassdrugadministrationtoeliminatelymphaticfilariasisinfijiamethodologicalapproach AT ericrafai lotqualityassurancesamplingtoassesscoverageandcompliancefollowingmassdrugadministrationtoeliminatelymphaticfilariasisinfijiamethodologicalapproach AT ilisapecikubuabola lotqualityassurancesamplingtoassesscoverageandcompliancefollowingmassdrugadministrationtoeliminatelymphaticfilariasisinfijiamethodologicalapproach AT mosesesalusalu lotqualityassurancesamplingtoassesscoverageandcompliancefollowingmassdrugadministrationtoeliminatelymphaticfilariasisinfijiamethodologicalapproach AT sunghyekim lotqualityassurancesamplingtoassesscoverageandcompliancefollowingmassdrugadministrationtoeliminatelymphaticfilariasisinfijiamethodologicalapproach AT maryhamerhodges lotqualityassurancesamplingtoassesscoverageandcompliancefollowingmassdrugadministrationtoeliminatelymphaticfilariasisinfijiamethodologicalapproach |